The stock price of Ranbaxy (OTC:RBXLY), subsidiary of Japan based Daiichi Sankyo (OTCPK:DSKYF) is up 30 percent over the last 3 months (as against 13.1% by other specialty generic companies) and I believe this is an opportune time for investors to cash in. The run up is in expectation of a turnaround driven by a few first to file (FTF) generic drug launches (Nexium and Valcyte generics) and upside from a strong ramp up of its acne drug Absorica (Isotretinoin) in the US. I believe there is over optimism surrounding the stock and it makes sense to exit,
· There is a strong chance that Ranbaxy may not be able to capitalize on...
Only subscribers can access this article, which is part of the PRO research library covering 3,604 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: